

Lars Henrik Jensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2404099/publications.pdf>

Version: 2024-02-01

94
papers

3,906
citations

361413

20
h-index

138484

58
g-index

97
all docs

97
docs citations

97
times ranked

4868
citing authors

#	ARTICLE	IF	CITATIONS
1	The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , 2022, 13, 18-31.	1.8	3
2	Impact of Open Dialogue about Complementary Alternative Medicine" A Phase II Randomized Controlled Trial. <i>Cancers</i> , 2022, 14, 952.	3.7	4
3	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	10.7	282
4	Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2): protocol for a randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e059960.	1.9	0
5	A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). <i>ESMO Open</i> , 2022, 7, 100529.	4.5	23
6	Cross-sectoral video consultations in cancer care: perspectives of cancer patients, oncologists and general practitioners. <i>Supportive Care in Cancer</i> , 2021, 29, 107-116.	2.2	9
7	KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6-6.	1.6	39
8	Randomized <scp>Phase II</scp> trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without <scp>KRAS</scp> exon 2 mutations. <i>International Journal of Cancer</i> , 2021, 149, 119-126.	5.1	8
9	Cross-sectoral communication by bringing together patient with cancer, general practitioner and oncologist in a video-based consultation: a qualitative study of oncologists'™ and nurse specialists'™ perspectives. <i>BMJ Open</i> , 2021, 11, e043038.	1.9	2
10	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 665-677.	10.7	110
11	Treosulfan in platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002395.	2.5	1
12	Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3500-3500.	1.6	51
13	Functional precision medicine in colorectal cancer based on patient-derived tumoroids and in-vitro sensitivity drug testing.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15567-e15567.	1.6	1
14	An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 181-197.	2.3	36
15	Early, integrated palliative rehabilitation improves quality of life of patients with newly diagnosed advanced cancer: The Pal-Rehab randomized controlled trial. <i>Palliative Medicine</i> , 2021, 35, 1344-1355.	3.1	19
16	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021, 149, 128-133.	2.8	20
17	Re"exposure to immunotherapy in metastatic colon cancer: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04349.	0.5	2
18	Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin: a non-randomised phase II clinical trial. <i>BMJ Open</i> , 2021, 11, e046779.	1.9	13

#	ARTICLE	IF	CITATIONS
19	PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177. <i>Annals of Oncology</i> , 2021, 32, S284.	1.2	0
20	Lynch syndrome-associated epithelial ovarian cancer and its immunological profile. <i>Gynecologic Oncology</i> , 2021, 162, 686-693.	1.4	10
21	The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5100.	3.7	5
22	Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer. <i>Cancers</i> , 2021, 13, 5492.	3.7	17
23	Cross-sectoral video consultation in cancer care: GPs™ evaluation of a randomised controlled trial. <i>BJGP Open</i> , 2021, 5, BJGPO.2020.0114.	1.8	2
24	Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 556-563.	0.8	32
25	Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. <i>Acta Oncologica</i> , 2020, 59, 298-301.	1.8	3
26	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	27.0	1,513
27	Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial. <i>Cancers</i> , 2020, 12, 1975.	3.7	17
28	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 5655-5667.	7.0	21
29	The impact of mismatch repair status to the preoperative staging of colon cancer: implications for clinical management. <i>Colorectal Cancer</i> , 2020, 9, CRC20.	0.8	3
30	The Clinical Impact of MicroRNA-21 in Low Rectal Cancer Treated with High-Dose Chemoradiotherapy in the Organ Preserving Setting. <i>Gastrointestinal Disorders</i> , 2020, 2, 378-384.	0.8	0
31	Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091847.	3.2	26
32	Study protocol: a randomized controlled trial comparing the efficacy of therapist guided internet-delivered cognitive therapy (TG-iConquerFear) with augmented treatment as usual in reducing fear of cancer recurrence in Danish colorectal cancer survivors. <i>BMC Cancer</i> , 2020, 20, 223.	2.6	6
33	Open dialogue about complementary and alternative medicine (CAM) integrated in conventional oncology care, characteristics and impact. A systematic review. <i>Patient Education and Counseling</i> , 2020, 103, 2224-2234.	2.2	13
34	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.7	25
35	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA4-LBA4.	1.6	150
36	Investigating whether shared video-based consultations with patients, oncologists, and GPs can benefit patient-centred cancer care: a qualitative study. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101023.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1445-1449.	0.5	3
38	NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1649.	3.7	17
39	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , 2019, 12, 968-972.	3.7	15
40	Improving continuity by bringing the cancer patient, general practitioner and oncologist together in a shared video-based consultation " protocol for a randomised controlled trial. <i>BMC Family Practice</i> , 2019, 20, 86.	2.9	9
41	Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	7
42	Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study. <i>BMC Cancer</i> , 2019, 19, 1163.	2.6	14
43	A new model of early, integrated palliative care: palliative rehabilitation for newly diagnosed patients with non-resectable cancer. <i>Supportive Care in Cancer</i> , 2019, 27, 3291-3300.	2.2	20
44	Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment. <i>Clinical Colorectal Cancer</i> , 2019, 18, 28-33.e3.	2.3	9
45	Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib. <i>Acta Radiologica</i> , 2019, 60, 836-845.	1.1	2
46	MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. , 2019, 2, 885-896.		0
47	Prognostic impact of SOX9 in stage II colon cancer: Results from a large nationwide cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15165-e15165.	1.6	0
48	How participatory action research changed our view of the challenges of shared decision-making training. <i>Patient Education and Counseling</i> , 2018, 101, 639-646.	2.2	16
49	Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. <i>British Journal of Cancer</i> , 2018, 119, 1367-1373.	6.4	30
50	Tumor"stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. <i>Acta Oncol"gica</i> , 2018, 57, 528-533.	1.8	36
51	A single-center randomized clinical trial of palliative rehabilitation versus standard care alone in patients with newly diagnosed non-resectable cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 75-75.	1.6	4
52	Natural killer cell activity: A test for immune reactivity with clinical perspectives.. <i>Journal of Clinical Oncology</i> , 2018, 36, 87-87.	1.6	1
53	Tumor specific methylation of NPY compared to RAS mutation in plasma DNA in the monitoring of colorectal cancer patients treated with last-line regorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15541-e15541.	1.6	0
54	Correlation between natural killer cell activity and treatment effect in patients with disseminated cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12029-12029.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Prognostic impact of CDX2 in stage II colon cancer: Results from two nationwide cohorts.. Journal of Clinical Oncology, 2018, 36, 3610-3610.	1.6	0
56	The prognostic value of simultaneous tumor and serum <scp>RAS</scp>/<scp>RAF</scp> mutations in localized colon cancer. Cancer Medicine, 2017, 6, 928-936.	2.8	15
57	Local staging of sigmoid colon cancer using MRI. Acta Radiologica Open, 2017, 6, 205846011772095.	0.6	22
58	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer, 2017, 17, 262.	2.6	16
59	A parallel-group randomized clinical trial of individually tailored, multidisciplinary, palliative rehabilitation for patients with newly diagnosed advanced cancer: the Pal-Rehab study protocol. BMC Cancer, 2017, 17, 560.	2.6	17
60	Monitoring the effect of first-line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.. Journal of Clinical Oncology, 2017, 35, 3593-3593.	1.6	0
61	Postponement of death weighed against duration of treatment and toxicity as key components in shared decision making about last line oncologic treatment.. Journal of Clinical Oncology, 2017, 35, e21555-e21555.	1.6	0
62	The prognostic impact of RAS and RAF serum mutations in localized colon cancer. Annals of Oncology, 2016, 27, vi27.	1.2	0
63	Extended RAS and BRAF mutation analysis of circulating tumor DNA in patients with biliary tract cancer. Annals of Oncology, 2016, 27, vi235.	1.2	0
64	Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. Expert Opinion on Investigational Drugs, 2016, 25, 359-365.	4.1	4
65	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	1.2	88
66	Feasibility of molecular patient selection in rare cancers: Phase II study of gemcitabine, oxaliplatin and capecitabine in KRAS mutated biliary tract cancer.. Journal of Clinical Oncology, 2016, 34, e15620-e15620.	1.6	0
67	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer, 2015, 51, 1381-1388.	2.8	19
68	High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncology, The, 2015, 16, 919-927.	10.7	435
69	Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta OncolÃ³gica, 2015, 54, 1747-1753.	1.8	84
70	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 2015, 15, 564.	2.6	182
71	Randomized phase II crossover trial exploring the clinical benefit from targeting EGFR or VEGF with combination chemotherapy in patients with non-resectable biliary tract cancer.. Journal of Clinical Oncology, 2015, 33, 4071-4071.	1.6	7
72	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. Journal of Clinical Oncology, 2015, 33, TPS4140-TPS4140.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma. <i>Acta Oncologica</i> , 2014, 53, 1448-1450.	1.8	6
74	Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. <i>Clinical Biochemistry</i> , 2014, 47, 599-604.	1.9	7
75	<i>BRAF</i> refines clinical interpretation of mismatch repair deficiency in colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 1-4.	0.8	2
76	Effectiveness study of gemcitabine, oxaliplatin, and capecitabine as first-line treatment for nonresectable biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 334-334.	1.6	0
77	A marker-driven phase II trial of neoadjuvant chemotherapy in locally advanced colon cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3621-3621.	1.6	1
78	Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 411-419.	4.4	18
79	Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. <i>Annals of Oncology</i> , 2012, 23, 2341-2346.	1.2	89
80	Biliary-tract cancer: improving therapy by adding molecularly targeted agents. <i>Lancet Oncology</i> , The, 2012, 13, 118-119.	10.7	5
81	A Phase II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. <i>Acta Oncologica</i> , 2011, 50, 448-454.	1.8	17
82	The relationship between serum vascular endothelial growth factor A and microsatellite instability in colorectal cancer. <i>Colorectal Disease</i> , 2011, 13, 984-988.	1.4	8
83	Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer. <i>Tumor Biology</i> , 2011, 32, 977-983.	1.8	6
84	Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 589-600.	2.4	10
85	EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2010, 21, 535-539.	1.2	30
86	Molecular biology from bench-to bedside – Which colorectal cancer patients should be referred for genetic counselling and risk assessment. <i>European Journal of Cancer</i> , 2010, 46, 1823-1828.	2.8	15
87	Clinical outcome in 520 consecutive Danish rectal cancer patients treated with short course preoperative radiotherapy. <i>European Journal of Surgical Oncology</i> , 2010, 36, 237-243.	1.0	12
88	Molecular Screening for Lynch Syndrome: From Bench to Bedside. <i>Journal of Clinical Oncology</i> , 2009, 27, e224-e224.	1.6	7
89	The prognostic importance of thymidylate gene polymorphism in colon cancer stage II. <i>International Journal of Colorectal Disease</i> , 2008, 23, 1267-1267.	2.2	0
90	Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. <i>Colorectal Disease</i> , 2008, 10, 490-497.	1.4	39

#	ARTICLE	IF	CITATIONS
91	Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer, 2008, 62, 85-91.	2.0	50
92	Microsatellite Instability and the Association with Plasma Homocysteine and Thymidylate Synthase in Colorectal Cancer. Cancer Investigation, 2008, 26, 583-589.	1.3	12
93	Predictive Value of MSH2 Gene Expression in Colorectal Cancer Treated with Capecitabine. Clinical Colorectal Cancer, 2007, 6, 433-435.	2.3	13
94	Laser microdissection and microsatellite analysis of colorectal adenocarcinomas. Anticancer Research, 2006, 26, 2069-74.	1.1	12